![Francesco Maria Lavino](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Francesco Maria Lavino
Director Ejecutivo en F2G Ltd. .
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Patrick Volkert Vink | M | 60 |
F2g Inc.
F2G Ltd.
![]() F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | 9 años |
Pamela Craig | F | 67 | 9 años | |
Paul Rothman | M | 65 | 9 años | |
Chirfi Guindo | M | 58 | 13 años | |
John H. Rex | M | - |
F2G Ltd.
![]() F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | - |
Saiyed Mahmood | M | 48 |
F2G Ltd.
![]() F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | - |
Allan Gabor | M | - | 11 años | |
Camilla Soenderby | F | - |
F2G Ltd.
![]() F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | 3 años |
Peter Dannenbaum | M | - | 7 años | |
Anderson Timothy | M | - |
F2G Ltd.
![]() F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | - |
Richard DeLuca | M | 61 | 13 años | |
Sylvie Grégoire | M | 62 |
F2G Ltd.
![]() F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | - |
Ralf Schmid | M | 57 |
F2G Ltd.
![]() F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | 8 años |
Simona Heidempergher | F | 56 |
F2G Ltd.
![]() F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | - |
Mike Birch | M | - |
F2G Ltd.
![]() F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | - |
Dean Li | M | 62 | 7 años | |
Tony Kennedy | M | - |
F2G Ltd.
![]() F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | - |
Naveed Iqbal Siddiqi | M | - |
F2G Ltd.
![]() F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | - |
Will West | M | - |
F2G Ltd.
![]() F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | - |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Robert Perez | M | 59 | 12 años | |
Michael Bonney | M | 65 | 20 años | |
Michael Tomsicek | M | 58 | 5 años | |
Thomas DesRosier | M | 69 | 2 años | |
Richard Clark | M | 77 | 6 años | |
David McGirr | M | 69 | 12 años | |
Lonnie Moulder | M | 66 | 5 años | |
Taylor Sandison | M | 52 | 1 años | |
John Noseworthy | M | 71 | - | |
Michael Nally | M | 48 | 10 años | |
Alison Lawton | F | 62 | 2 años | |
Nancy Hutson | M | 74 | 7 años | |
Mark Corrigan | M | 66 | 7 años | |
Jane Ellen Henney | M | 76 | 2 años | |
Martin Rosenberg | M | 78 | 9 años | |
Ian James Nicholson | M | 64 |
F2G Ltd.
![]() F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | 8 años |
Thomas Shenk | M | 77 | 11 años | |
Natarajan Sethuraman | M | 62 | 10 años | |
J. Singleton | M | 71 | 11 años | |
Michael B. Wood | M | 78 | 9 años | |
Sheila Ranganath | F | - | 5 años | |
Harry R. Jacobson | M | 76 | 3 años | |
Brian Piekos | M | 49 | 5 años | |
Steven Goldstone | M | 78 | 6 años | |
Charles Kidder | M | 79 | 12 años | |
Arthur Santora | M | 73 | 28 años | |
René Russo | M | 49 | 12 años | |
Guy Patrick M. Eiferman | M | - | 4 años | |
Timothy Murphy | M | 56 | 4 años | |
Sachin Jain | M | 43 | 2 años | |
Milenko Cicmil | M | - | - | |
Larry G. Edwards | M | 52 | 1 años | |
Hugo Wahnish | M | - | 18 años | |
Yao Lee | M | 54 | 3 años | |
James Swanson | M | 58 | 8 años | |
Carlos Lugo | M | - | 2 años | |
Thomas Cannell | M | 62 | 1 años | |
John Renger | M | 55 | 15 años | |
William Steinkrauss | M | 39 | 3 años | |
Arnaub Chatterjee | M | - | 5 años | |
Marvin Johnson | M | 61 | 2 años | |
Joseph Eid | M | 56 | - | |
David Parry | M | - | 2 años | |
Jerald Korn | M | 45 | 2 años | |
Yanni Souroutzidis | M | - | 2 años | |
Lucinda Quan | F | 51 | 2 años | |
Bumpus Durso | F | 54 | 6 años | |
Quentin Roach | M | 57 | 4 años | |
Daniel Pascheles | M | - | 11 años | |
Steven Hubrig Koehler | M | 73 | 2 años | |
Renu Vaish | F | - | 1 años | |
Richard Kender | M | 68 | 35 años | |
Peter Kim | M | 65 | 5 años | |
Martin Duvall | M | 62 | 1 años | |
Mary Thistle | F | 64 | 6 años | |
Joseph Farmer | M | 52 | 3 años | |
Willie Deese | M | 68 | 12 años | |
James Christopher Scalet | M | 65 | 9 años | |
Angelique M. Carbo | F | 59 | 2 años | |
Christina Morrison | F | 57 | 4 años | |
Pam Cheng | F | 53 | 5 años | |
Michael Rosenblatt | M | 76 | 32 años | |
Roy Baynes | M | 69 | - | |
C. Nicholson | M | 69 | 2 años | |
Mervyn Turner | M | 77 | 2 años | |
Michael Holston | M | 61 | 6 años | |
Andrew Davis | M | 38 | 1 años | |
Cuong Viet Do | M | 58 | 3 años | |
Simon D. Kelner | M | 51 | 13 años | |
Charles Laranjeira | M | 58 | 4 años | |
Kathleen Metters | M | 66 | 13 años | |
Roger Pomerantz | M | 67 | 3 años | |
Pernilla Sandwall | F | 61 | 8 años | |
Geralyn S. Ritter | F | - | 8 años | |
Jason Pesile | M | 50 | 2 años | |
Terrie Curran | F | 55 | 4 años | |
Graham Lumsden | M | 64 | 26 años | |
D. Gilliland | M | 69 | 4 años | |
Nancy Thornberry | F | 67 | 9 años | |
Barry Goldstein | M | - | 5 años | |
Jonathan Robbins | M | - | 6 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 88 | 88.00% |
Reino Unido | 13 | 13.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Francesco Maria Lavino
- Red Personal